The study, which was carried out by scientists at Queen's University Belfast, the University of Ulster, the Belfast Health and Social Care Trust and teams of researchers in Europe, USA and Australia found significant improvement in lung function, quality of life and a reduction in disease flare ups for those receiving the new treatment.
The drug (VX-770) is a significant breakthrough not only for those with the 'Celtic Gene', known as G551D, but also for all other Cystic Fibrosis sufferers as it indicates that the basic defect in Cystic Fibrosis can be treated. This is the first drug aimed at the basic defect in Cystic Fibrosis to show an effect. It is still too early to determine whether this treatment will improve life expectancy but the improvements in the breathing tests and the reduction in flare-ups would suggest survival will be better.
Stuart Elborn, Centre Director in the Centre for Infection and Immunity at Queen's University and co-leader of the study said: "The development of this drug is significant because it is the first to show that treating the underlying cause of Cystic Fibrosis may have profound effects on the disease, even among people who have been living with it for decades. The remarkable reductions in sweat chloride observed in this study support the idea that VX-770 improves protein function thereby addressing the fundamental defect that leads to CF."
Dr Judy Bradley, from the University of Ulster said: "This drug opens the defective channel in the lung cells of people with Cystic Fibrosis and allows proper lung clearance of bacteria. This is a ground breaking treatment because it treats the basic defect caused by the gene mutation in patients. Correcting the cells with this mutation shows that treatments aimed at the basic mutation can work leading to improvements in lung function and symptoms."
Dr Damien Downey, from the Belfast Health and Social Care Trust said: "The success of this study illustrates the benefits that come from collaborative work here in Northern Ireland. Not only will this breakthrough help patients in Ireland and the UK but it has the potential to change the lives for those with Cystic Fibrosis around the world. As a result of the recent work researchers from Queen's University, University of Ulster and clinicians from Belfast Health and Social Care Trust have been selected to join the European Cystic Fibrosis Society Clinical Trials Network. This means Cystic Fibrosis researchers in Northern Ireland will be collaborating with their European counterparts to work toward improved treatments for Cystic Fibrosis on a global level. "
The new drug will be submitted for licensing in the Autumn of this year and is expected to be available to patients by as early next year.
For media inquiries please contact Claire O'Callaghan on 00 44 (0) 2890975391 / 07814422572 or email@example.com
Notes to Editors:
1. Cystic Fibrosis affects approximately 70,000 people worldwide. It is Ireland's most common life-threatening genetically inherited disease, and one of the most common in the UK. Over 9000 people in the UK have Cystic Fibrosis and over 1100 people in Ireland. Ireland has the highest proportion of CF people in the world.
2. Professor Stuart Elborn is available for interview. Interview bids to Claire O'Callaghan on 00 44 (0) 2890975391 / 07814422572 or firstname.lastname@example.org
3. Dr Judy Bradley is available for interview. Interview bids to David Young on 00 44 (0) 2890366074
4. This was an international study involving the US, Europe and Australia. Professor Stuart Elborn, Centre Director in the Centre for Infection and Immunity at Queen's University was the co-lead with Dr Bonny Ramsey from the University of Washington in Seattle. As well as leading the clinical trial patients were recruited from the Belfast Trust and the study was undertaken by a team of researchers from Queen's University, University of Ulster and Belfast Health and Social Care Trust.
5. Queen's University Belfast, University of Ulster and the Belfast Health and Social Care Trust through the Research and Development Office run a clinical research network in respiratory medicine. The majority of clinical trials in this local network are in patients with Cystic Fibrosis. The success of this local network has resulted in selection to join the European Cystic Fibrosis Society European Clinical Trials Network which is based in the University of Leuven in Belgium. This will provide people with Cystic Fibrosis in Northern Ireland the opportunity to participate in more clinical trials which we would anticipate would transform the lives of people with Cystic Fibrosis.
Claire O'Callaghan | EurekAlert!
Chances to treat childhood dementia
24.07.2017 | Julius-Maximilians-Universität Würzburg
World first: Massive thrombosis removed during early pregnancy
20.07.2017 | Universitätsspital Bern
21.07.2017 | Event News
19.07.2017 | Event News
12.07.2017 | Event News
24.07.2017 | Power and Electrical Engineering
24.07.2017 | Materials Sciences
24.07.2017 | Materials Sciences